2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Molecular Testing, Cell Expansion, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Immunology, Immunodeficiency, Infectious Diseases, Viral, Bacterial, Fungal, Other Pathogens, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Measurable Residual Disease, ALL, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

6277 Is there an association between Medicaid expansion and better overall survival in patients with diffuse large B-cell lymphoma? a real-world database result using the national cancer database with difference-in-differences analysis

Carolina Velez-Mejia, MD, Luis Mario Villela Martinez, MD, PhD2, Qianqian Liu, PhD3, Joel Michalek, PhD4, Adolfo Diaz Duque, MD, MSc5
1 Virginia Commonwealth University, Richmond, Virginia, United States
2 Universidad Autonoma de Sinaloa, Culiacán, Mexico
3 UT Health San Antonio, San Antonio, Texas, United States
4 UT Health San Antonio, San Antonio, Texas, United States
5 Mays Cancer Center, San Antonio, Texas, United States

Background:

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma in adults, requiring timely access to specialized treatment to optimize outcomes. It is known that socioeconomic status and insurance coverage has influenced throughout the years to access care and hence, the outcomes for patients with DLBCL. The implementation of the 2014 Affordable Care Act (ACA) Medicaid expansion significantly increased healthcare coverage across the United States, yet its long-term impact for patients with DLBCL has not yet been evaluated. This study evaluates the impact of Medicaid expansion on population-level trends, demographics, clinical presentation, and overall survival outcomes in patients diagnosed with DLBCL.

 

Methods:

We performed a retrospective cohort study using the National Cancer Database (2004–2023) of adult patients diagnosed with DLBCL. We stratified patients depending on their location following the Medicaid expansion status:  patients in pre-expansion states (2004–2013) and post-expansion states (2014–2023). Baseline demographic, socioeconomic, and clinical characteristics were compared between groups. Overall survival was estimated using the Kaplan-Meier analysis with log-rank testing. Difference-in-differences analysis was performed to evaluate the independent association of Medicaid expansion with survival while accounting for national temporal trends.

  

Results:

A total of 310,743 patients with DLBCL were included in the analysis, with 132,173 (43%) diagnosed before Medicaid expansion and 178,570 (58%) diagnosed after. Overall, 235,822 (76%) patients resided in expansion states and 74,921 (24%) in non-expansion states. Before 2014, 101,447 (77%) patients lived in expansion states compared with 30,726 (23%) in non-expansion states; after 2014, these proportions shifted to 134,375 (75%) and 44,195 (25%), respectively [p<0.001]. 

Over time, median age at diagnosis increased from 69 to 70 years [p<0.001], female representation decreased from 47% to 44% [p<0.001], and Hispanic representation increased from 6% to 8% [p<0.001] in pre-expanded territory vs post expanded, respectively.  Following expansion, care at academic cancer centers increased from 54% to 57% [p<0.001], government-sponsored insurance coverage rose from 61% to 68%, and the uninsured rate declined from 3% to 2% [p<0.001]. Significant temporal differences were also observed in household income, educational attainment, urban residence, and comorbidity burden [all p<0.001].

Patients diagnosed post-2014 were more likely to present with stage IV disease (40% vs 32%) and less likely to present with stage I disease (18% vs 22%) [p<0.001].

Prior to Medicaid expansion, patients in expansion states demonstrated superior overall survival (OS) compared to those in non-expansion states [log-rank p=0.00055]. Following ACA implementation, OS became comparable between expansion and non-expansion states [log-rank p=0.01], with adjusted Kaplan-Meier curves showing near-complete convergence, suggesting an attenuation of pre-existing disparities.

Overall survival improved across both cohorts over time. In expansion states, estimated OS increased at 2 years (63% to 66%), 5 years (53% to 55%), and 10 years (39% to 41%). In non-expansion states, corresponding OS improvements were seen at 2 years (63% to 65%), 5 years (52% to 54%), and 10 years (38% to 40%). However, difference-in-differences analysis demonstrated no statistically significant additional survival benefit attributable specifically to Medicaid expansion beyond nationwide improvements in DLBCL outcomes.

 

Conclusions:

Overall survival for patients with DLBCL has improved throughout the years, regardless of the location of patients in pre/post expansion states. While patients in expansion states held a baseline survival advantage pre-2014, post ACA the outcomes converged and eliminated this gap. Ultimately, difference-in-differences analysis showed no independent survival benefit from Medicaid expansion. These findings suggest that nationwide therapeutic advances and systemic care improvements were the primary drivers of reduced historical survival disparities in DLBCL, rather than state-level insurance expansion alone. Although healthcare expansion policies improve insurance coverage and access to academic centers, further strategies are needed to address broader systemic factors driving survival in DLBCL.

Carolina Velez-Mejia, MD: No relevant conflicts of interest to declare.